Published in J Exp Med on April 01, 1991
Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest (1992) 1.84
Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell (2016) 1.57
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol (1995) 1.25
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Progress toward active or passive HIV-1 vaccination. J Exp Med (2016) 0.86
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine (2014) 0.81
Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology (2013) 0.76
Neutralization-Enhancing RF Antibodies for HIV Vaccines. Front Immunol (2014) 0.75
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol (2015) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature (1986) 10.62
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J Immunol (1986) 5.31
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1988) 4.72
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A (1986) 4.43
A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol Methods (1983) 4.39
Genetic variation in AIDS viruses. Cell (1986) 3.68
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science (1988) 3.08
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
HTLV-III, LAV, ARV are variants of same AIDS virus. Nature (1985) 2.03
Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol (1988) 1.95
Molecular cloning and primary nucleotide sequence analysis of a distinct human immunodeficiency virus isolate reveal significant divergence in its genomic sequences. Proc Natl Acad Sci U S A (1986) 1.61
Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses (1990) 1.60
Depressed interleukin 2 receptor expression in acquired immune deficiency and lymphadenopathy syndromes. J Immunol (1984) 1.49
Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis (1988) 1.49
Shared idiotypes and restricted immunoglobulin variable region heavy chain genes characterize murine autoantibodies of various specificities. J Clin Invest (1986) 1.48
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci U S A (1987) 1.37
Detection of native and denatured DNA antibody forming cells by the enzyme-linked immunospot assay. A clinical study of (New Zealand black x New Zealand white)F1 mice. Arthritis Rheum (1986) 1.24
Proliferation of anti-DNA-producing NZB B cells in a non-autoimmune environment. J Immunol (1986) 1.17
Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses (1988) 0.97
Generation of antibody diversity. I. Kinetics of production of different antibody specificities during the course of an immune response. Eur J Immunol (1974) 0.94
Novel ELISA and ELISA-spot assays used to quantitate B cells and serum antibodies specific for T cell and bromelated mouse red blood cell autoantigens. J Immunol Methods (1987) 0.93
Restricted neutralization of divergent HTLV-III/LAV isolates by antibodies to the major envelope glycoprotein. Haematol Blood Transfus (1987) 0.78
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res Hum Retroviruses (1990) 1.60
VH family utilization by IgG anti-DNA-secreting lymphocytes derived from autoimmune MRL-lpr/lpr mice. Arthritis Rheum (1993) 1.40
Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun (1999) 1.39
CpG motifs as immune adjuvants. Vaccine (1999) 1.30
Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J Immunol (1998) 1.20
Simultaneous determination of total IgE and allergen-specific IgE in serum by the MAST chemiluminescent assay system. Clin Chem (1985) 1.03
Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum (1991) 0.96
Increased activation and altered ratio of interferon-gamma: interleukin-4 secreting cells in MRL-lpr/lpr mice. Autoimmunity (1995) 0.90
Activation of interleukin 4- and interleukin 6-secreting cells by HIV-specific synthetic peptides. AIDS Res Hum Retroviruses (1995) 0.90
DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol (1997) 0.89
Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol (1999) 0.88
Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J Immunol (1998) 0.87
Comparative immunogenicity of gp120-derived proteins and their induction of anti-V3 loop region antibodies. J Acquir Immune Defic Syndr (1992) 0.82
Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. J Infect Dis (1996) 0.80
Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci (1998) 0.80
Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. J Acquir Immune Defic Syndr (1994) 0.77
Identification of a novel gp130-responsive site in the vasoactive intestinal peptide cytokine response element. J Biol Chem (2000) 0.77
Synergy of activin and ciliary neurotrophic factor signaling pathways in the induction of vasoactive intestinal peptide gene expression. Mol Endocrinol (2000) 0.76
Effect of cyclophosphamide, total body irradiation, and zidovudine on retrovirus proliferation and disease progression in murine AIDS. AIDS Res Hum Retroviruses (1992) 0.75
International EMS is called to action. JEMS (1989) 0.75
Safe and effective regulation of hematocrit by gene gun administration of an erythropoietin-encoding DNA plasmid. Hum Gene Ther (1999) 0.75
Inhibition of the offspring anti-recombinant gp120 antibody response to a human immunodeficiency virus vaccine by maternal immunization in a murine model. J Infect Dis (1995) 0.75
Cross-reactivity of IgG anti-DNA-secreting B cells in patients with systemic lupus erythematosus. Eur J Immunol (1994) 0.75
Biological activities of cystic fibrosis serum. III. CF serum induced uptake of 45Ca++ by rabbit tracheal explants. Biochem Biophys Res Commun (1979) 0.75
B-1a and conventional B cells from autoimmune NZB.H-2bm12 mice exhibit similar functional characteristics in vivo. Eur J Immunol (1993) 0.75
The biologic activities of cystic fibrosis serum. II. Ultrastructural aspects of the effect of cystic fibrosis sera and calcium ionophore A23187 on rabbit tracheal explants. Pediatr Res (1978) 0.75
State master's degree requirements for nurse anesthetists. AANA J (1998) 0.75